These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35735430)

  • 1. Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.
    Shanta K; Nakayama K; Hossain MM; Razia S; Ishibashi T; Ishikawa M; Yamashita H; Kanno K; Sato S; Nakayama S; Otsuki Y; Kyo S
    Curr Oncol; 2022 Jun; 29(6):4020-4033. PubMed ID: 35735430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone receptor expression profile of low-grade serous ovarian cancers.
    Buttarelli M; Mascilini F; Zannoni GF; Ciucci A; Martinelli E; Filippetti F; Scambia G; Ferrandina G; Gallo D
    Gynecol Oncol; 2017 May; 145(2):352-360. PubMed ID: 28228232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.
    Zwimpfer TA; Tal O; Geissler F; Coelho R; Rimmer N; Jacob F; Heinzelmann-Schwarz V
    Cancer Treat Rev; 2023 Jan; 112():102497. PubMed ID: 36525716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
    Sehouli J; Braicu EI; Richter R; Denkert C; Jank P; Jurmeister PS; Kunze CA; Budczies J; Darb-Esfahani S; Schmitt WD; Traut A; Grabowski J; Taube ET; Plett H
    Hum Pathol; 2019 Mar; 85():299-308. PubMed ID: 30428389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
    Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
    Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
    Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS
    Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin.
    Cheng JC; Auersperg N; Leung PC
    Oncogene; 2011 Mar; 30(9):1020-31. PubMed ID: 20972462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma.
    Voutsadakis IA
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():172-178. PubMed ID: 33246201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional estrogen receptor signaling pathway activity in high-grade serous ovarian carcinoma as compared to estrogen receptor protein expression by immunohistochemistry.
    van der Ploeg P; van Lieshout LAM; van de Stolpe A; Bosch SL; Lentjes-Beer MHFM; Bekkers RLM; Piek JMJ
    Cell Oncol (Dordr); 2021 Aug; 44(4):951-957. PubMed ID: 33723801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Frequency of
    Ishibashi T; Nakayama K; Razia S; Ishikawa M; Nakamura K; Yamashita H; Dey P; Iida K; Kurioka H; Nakayama S; Otsuki Y; Ishikawa N; Kyo S
    Diagnostics (Basel); 2019 Dec; 10(1):. PubMed ID: 31892193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
    Combe P; Chauvenet L; Lefrère-Belda MA; Blons H; Rousseau C; Oudard S; Pujade-Lauraine E
    Invest New Drugs; 2015 Dec; 33(6):1267-70. PubMed ID: 26490654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer.
    Chen S; Dai X; Gao Y; Shen F; Ding J; Chen Q
    Sci Rep; 2017 Dec; 7(1):16922. PubMed ID: 29208958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
    Lazurko C; Clark M; Pulman K; Lennox G; May T; Fazelzad R; Gien LT; Zigras T
    Gynecol Oncol; 2021 Oct; 163(1):209-214. PubMed ID: 34325937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
    Tang M; O'Connell RL; Amant F; Beale P; McNally O; Sjoquist KM; Grant P; Davis A; Sykes P; Mileshkin L; Moujaber T; Kennedy CJ; deFazio A; Tan K; Antill Y; Goh J; Bonaventura T; Scurry J; Friedlander M
    Gynecol Oncol; 2019 Sep; 154(3):531-538. PubMed ID: 31227223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
    Wong KK; Bateman NW; Ng CW; Tsang YTM; Sun CS; Celestino J; Nguyen TV; Malpica A; Hillman RT; Zhang J; Futreal PA; Rojas C; Conrads KA; Hood BL; Dalgard CL; Wilkerson MD; Phippen NT; Conrads TP; Maxwell GL; Sood AK; Gershenson DM
    J Transl Med; 2022 Dec; 20(1):606. PubMed ID: 36528667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.
    Nakayama K; Nakayama N; Kurman RJ; Cope L; Pohl G; Samuels Y; Velculescu VE; Wang TL; Shih IeM
    Cancer Biol Ther; 2006 Jul; 5(7):779-85. PubMed ID: 16721043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells.
    Dey P; Nakayama K; Razia S; Ishikawa M; Ishibashi T; Yamashita H; Kanno K; Sato S; Kiyono T; Kyo S
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
    Simpkins F; Hevia-Paez P; Sun J; Ullmer W; Gilbert CA; da Silva T; Pedram A; Levin ER; Reis IM; Rabinovich B; Azzam D; Xu XX; Ince TA; Yang JY; Verhaak RG; Lu Y; Mills GB; Slingerland JM
    Clin Cancer Res; 2012 Nov; 18(21):5911-23. PubMed ID: 22896656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.